Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2006

Open Access 01-06-2006 | Research

In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer

Authors: Christoph Loddenkemper, Martin Schernus, Michel Noutsias, Harald Stein, Eckhard Thiel, Dirk Nagorsen

Published in: Journal of Translational Medicine | Issue 1/2006

Login to get access

Abstract

The immune system spontaneously responds to tumor-associated antigens in peripheral blood of colorectal cancer (CRC) patients. Regulatory T cells (Treg) are suspected of influencing the interaction between the tumor and immune system and thus the course of malignant diseases. However, the function of Tregs in the development of T cell responses and on the clinical course of CRC is not clear. We analyzed Treg infiltration (FOXP3 staining) in situ in 40 CRC patients and investigated whether there is a correlation to disease stage, systemic T cell response, and survival. Treg infiltration was significantly higher in CRC than in healthy colon. Stromal Treg infiltration was significantly higher than epithelial infiltration in CRC. Furthermore, Treg infiltration in the tumor was significantly higher in limited disease than in metastatic CRC. The average Treg infiltration rate in the tumor was non-significantly higher in patients without systemic TAA-specific T cell response. Survival did not differ between patients with high Treg infiltration and those with low Treg infiltration. In conclusion, a direct link between Treg infiltration in the tumor and the development of a systemic T cell response in CRC cannot be proven. However, local Treg infiltration was significantly higher in limited disease, in which a systemic TAA-directed T cell responses is less frequently observed.
Appendix
Available only for authorised users
Literature
1.
Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T: Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol. 2005, 2: 108-13. 10.1038/ncponc0098.CrossRefPubMed
2.
Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U: Natural T cell immunity against cancer. Clin Cancer Res. 2003, 9: 4296-303.PubMed
3.
Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C: Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res. 2000, 60: 4850-4.PubMed
4.
Nagorsen D, Scheibenbogen C, Schaller G, Leigh B, Schmittel A, Letsch A, Thiel E, Keilholz U: Differences in T cell immunity towards tumor associated antigens between colorectal cancer and breast cancer. Int J Cancer. 2003, 105: 221-225. 10.1002/ijc.11052.CrossRefPubMed
5.
Nagorsen D, Scheibenbogen C, Letsch A, Germer CT, Buhr HJ, Hegewisch-Becker S, Rivoltini L, Thiel E, Keilholz U: T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med. 2005, 3: 3-10.1186/1479-5876-3-3.PubMedCentralCrossRefPubMed
6.
Nagorsen D, Thiel E: Clinical and immunological responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res. 2006, 12: 3064-9. 10.1158/1078-0432.CCR-05-2788.CrossRefPubMed
7.
Blankenstein T: The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol. 2005, 17: 180-6. 10.1016/j.coi.2005.01.008.CrossRefPubMed
8.
Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R: Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005, 128: 1868-78. 10.1053/j.gastro.2005.03.043.CrossRefPubMed
9.
Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, Steiner B, Berg E, Miehlke S, Bornhauser M, Schneider T, Zeitz M, Stein H, Thiel E, Duchmann R, Uharek L: Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006, 107: 1717-23. 10.1182/blood-2005-06-2529.CrossRefPubMed
10.
Nomura T, Sakaguchi S: Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol. 2005, 293: 287-302.PubMed
11.
Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003, 9: 606-12.PubMed
12.
Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003, 98: 1089-99. 10.1002/cncr.11618.CrossRefPubMed
13.
Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005, 65: 2457-64. 10.1158/0008-5472.CAN-04-3232.CrossRefPubMed
14.
Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T: CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep. 2005, 14: 1269-73.PubMed
15.
Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H: CD4(+)CD25(high) regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2006, 55: 1064-71. 10.1007/s00262-005-0092-8.CrossRefPubMed
16.
Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003, 9: 4404-8.PubMed
17.
Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999, 59: 3128-33.PubMed
18.
Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999, 163: 5211-8.PubMed
19.
Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295-307. 10.1038/nri1806.CrossRefPubMed
20.
Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, Shimizu J, Nomura T, Chiba T, Sakaguchi S: Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating FOXP3+CD25+CD4+ regulatory T cells. J Exp Med. 2005, 202: 885-91. 10.1084/jem.20050940.PubMedCentralCrossRefPubMed
21.
Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004, 200: 771-82. 10.1084/jem.20041130.PubMedCentralCrossRefPubMed
22.
Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004, 34: 336-44. 10.1002/eji.200324181.CrossRefPubMed
23.
Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005, 174: 2591-601.PubMedCentralCrossRefPubMed
24.
Nishikawa H, Jager E, Ritter G, Old LJ, Gnjatic S: CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 2005, 106: 1008-11. 10.1182/blood-2005-02-0607.CrossRefPubMed
25.
Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA. 2004, 101 (Suppl 2): 14639-45. 10.1073/pnas.0405730101.PubMedCentralCrossRefPubMed
26.
Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL: Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother. 2005, 54: 1072-81. 10.1007/s00262-005-0670-9.CrossRefPubMed
27.
Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX: Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005, 201: 779-91. 10.1084/jem.20041684.PubMedCentralCrossRefPubMed
28.
Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L: FOXP3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004, 173 (2): 1444-53.CrossRefPubMed
29.
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10: 942-9. 10.1038/nm1093.CrossRefPubMed
30.
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005, 102: 18538-43. 10.1073/pnas.0509182102.PubMedCentralCrossRefPubMed
31.
Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E, Marth C: The expression of the regulatory T cell-specific forkhead box transcription factor FOXP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005, 11: 8326-31. 10.1158/1078-0432.CCR-05-1244.CrossRefPubMed
32.
Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997, 182: 318-24. 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6.CrossRefPubMed
33.
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58: 3491-3494.PubMed
34.
Oberg A, Samii S, Stenling R, Lindmark G: Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis. 2002, 17: 25-9. 10.1007/s003840100337.CrossRefPubMed
35.
Diederichsen AC, Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C: Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother. 2003, 52: 423-8. 10.1007/s00262-003-0388-5.CrossRefPubMed
36.
Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE: Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003, 10: 309-13.PubMed
37.
Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y, Satomi S: Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer. 2004, 91: 1711-7.PubMedCentralPubMed
38.
Loddenkemper C, Maul J, Berg E, Stein H, Zeitz M, Duchmann R: Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. Eur J Immunol. 2006, 36: 245-10.1002/eji.200535651.CrossRefPubMed
39.
Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor FOXP3. Science. 2003, 299: 1057-61. 10.1126/science.1079490.CrossRefPubMed
40.
Fontenot JD, Gavin MA, Rudensky AY: FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003, 4: 330-6. 10.1038/ni904.CrossRefPubMed
41.
Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003, 4: 337-42. 10.1038/ni909.CrossRefPubMed
42.
Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y, Tomczak M, Rogers AB, Horwitz BH, Fox JG: CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 2003, 63: 6042-50.PubMed
43.
Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C, Piris MA: Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005, 11: 1467-73. 10.1158/1078-0432.CCR-04-1869.CrossRefPubMed
44.
Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH: High numbers of tumor infiltrating FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood. 2006 Jul 6,
45.
Whiteside TL: The role of immune cells in the tumor microenvironment. Cancer Treat Res. 2006, 130: 103-24.CrossRefPubMed
46.
Lu H, Ouyang W, Huang C: Inflammation, a key event in cancer development. Mol Cancer Res. 2006, 4: 221-33. 10.1158/1541-7786.MCR-05-0261.CrossRefPubMed
47.
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005, 353: 2654-66. 10.1056/NEJMoa051424. Comment in: N Engl J Med 2005;353:2640-1. N Engl J Med 2006;354:1531-2; author reply 1531-2CrossRefPubMed
Metadata
Title
In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer
Authors
Christoph Loddenkemper
Martin Schernus
Michel Noutsias
Harald Stein
Eckhard Thiel
Dirk Nagorsen
Publication date
01-06-2006
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2006
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-4-52

Other articles of this Issue 1/2006

Journal of Translational Medicine 1/2006 Go to the issue

Research

Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin

Research

Combined IL-21 and Low-Dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

Research

Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas

Research

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Review

Hydralazine target: From blood vessels to the epigenome

Research

Decreased wheel-running activity in hamsters post myocardial infarction
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits